Beyond ADMET: AI for medicines safety - survey

We use some essential cookies to make this website work. We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services. We also use cookies set by other sites to help us deliver content from their services. You have accepted additional cookies. You can change your cookie settings at any time. You have rejected additional cookies. You can change your cookie settings at any time. Get emails about this page Summary The MHRA and the Regulatory Innovation Office (RIO) invite organisations to share their views on the use of artificial intelligence (AI) in medicines development. This call for evidence closes at 5pm on 22 December 2026 AI has the potential to improve medicines safety evaluation, including the prediction and assessment of a medicine’s absorption, distribution, metabolism, excretion and toxicity (ADMET), by integrating traditional preclinical data with clinical and real-world data which reflects the variability across populations, disease states and clinical conditions. This could provide new ways to predict how medicines behave in the body and perform in real-world settings, across different populations and clinical conditions, and help identify potential safety risks earlier. We are interested in understanding how organisations are currently using, developing or planning to use AI based approaches, as well as the barriers or challenges they face. This includes areas such as model development, validation, access to data, data sharing and regulatory considerations. The findings will inform the development of the ‘Beyond ADMET: AI for medicines safety’ regulatory sandbox, announced in June 2026 , and support future regulatory work in this area. They will also help shape future engagement with innovators and researchers, including workshops and other opportunities to explore key issues in more detail. We welcome views from organisations involved across the medicines development pathway, including toxicology, preclinical and clinical research and testing, as well as life sciences, biotechnology, AI and other related sectors. Please share perspectives and experiences that are relevant to your organisation. Where possible, provide examples to help us understand current practice, challenges and priorities. You do not need to be using AI for medicines safety-related approaches today to respond. We are also interested in future plans and areas of unmet need. The deadline for completing the questionnaire is 11:59pm (UK time) Tuesday 22 December 2026. https://www.surveys.mhra.gov.uk/6a96d31d5f8f3771f000f83a The following links open in a new tab Share on Facebook (opens in new tab) Share on X (opens in new tab) Updates to this page Published 22 September 2026 Sign up for emails or print this page Get emails about this page Print this page Is this page useful? Maybe Yes this page is useful No this page is not useful Thank you for your feedback Report a problem with this page Help us improve GOV.UK Do not include personal or financial information like your National Insurance number or credit card details. To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab and requires JavaScript ) .